A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

December 30, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

January 31, 2026

Conditions
Advanced Gastric Cancer
Interventions
DRUG

Transcatheter Arterial Chemoembolization

"Patients will sequentially receive one cycle TACE (3 weeks), one cycle SOX regimen (3 weeks), one cycle TACE (3 weeks) and one cycle SOX (3 weeks) regimen, a total of 12-week neoadjuvant therapy.~TACE cycle: Day 1: trans-femorally performed with infusion of oxaliplatin (85 mg/m2) into tumor blood vessels. Then, Embosphere® Microspheres (300-500 μm) will be injected for embolism. Day 1-14: Oral Tegafur Gimeracil Oteracil Potassium Capsule 40-60 mg bid.~SOX cycle: Day 1: Oxaliplatin 130mg/m2 intravenous. Day 1-14: Oral Tegafur gimeracil oteracil potassium capsule 40-60 mg bid."

DRUG

Tislelizumab

PD-1 antibody Tislelizumab will be administrated by 200mg, ivgtt, q3w throughout 12-week neoadjuvant treatment.

Trial Locations (1)

200032

RECRUITING

ZhongShan hospital Fudan university, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER